{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:30:26Z","timestamp":1788489026327,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2851,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1093\/annonc\/mdr148","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T03:55:02Z","timestamp":1304567702000},"page":"458-463","source":"Crossref","is-referenced-by-count":62,"title":["Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Khasraw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Holodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Goldlust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr148_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11912-009-0077-4","article-title":"Advances in the treatment of malignant gliomas","volume":"12","author":"Khasraw","year":"2010","journal-title":"Curr Oncol Rep"},{"key":"10.1093\/annonc\/mdr148_bb0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdr148_bb0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1215\/15228517-2008-010","article-title":"What is the risk of intracranial bleeding during anti-VEGF therapy?","volume":"10","author":"Carden","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16(1)","author":"Besse","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr148_bb0035","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.0b013e3181cef837","article-title":"Intracerebral and subarachnoid hemorrhage in patients with cancer","volume":"74","author":"Navi","year":"2010","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdr148_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-2004-861539","article-title":"Cerebrovascular complications in patients with cancer","volume":"24","author":"Rogers","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1093\/annonc\/mdr148_bb0050","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1200\/JCO.2009.22.0616","article-title":"Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdr148_bb0060","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-07-0847","article-title":"Platelets take up the monoclonal antibody bevacizumab","volume":"13","author":"Verheul","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr148_bb0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0958-1669(00)00153-1","article-title":"VEGF: an update on biological and therapeutic aspects","volume":"11","author":"Ferrara","year":"2000","journal-title":"Curr Opin Biotechnol"},{"key":"10.1093\/annonc\/mdr148_bb0070","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14740338.5.4.553","article-title":"Incidence and management of bevacizumab-related toxicities in colorectal cancer","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1093\/annonc\/mdr148_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0080","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr148_bb0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr148_bb0090","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/2\/458\/553855\/mdr148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:29:16Z","timestamp":1624692556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0923753419344023"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr148","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}